This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
Nektar Therapeutics Identifier:
First received: December 4, 2008
Last updated: August 12, 2014
Last verified: August 2014

This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced breast cancer whose disease has failed prior taxane-based treatment in the metastatic setting.

Patients will be randomized 1:1 into one of two treatment arms. NKTR 102 will be administered at a dose level of 145 mg/m2 in both arms. In Arm A, NKTR-102 will be given on a q14d schedule. In Arm B, NKTR-102 will be given on a q21d schedule. Approximately 70 patients may be evaluated in this study with approximately 35 patients enrolled in each treatment arm.

Condition Intervention Phase
Tumor Breast Cancer Drug: NKTR-102 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Breast Cancer Whose Disease Has Failed Prior Taxane-Based Treatment

Resource links provided by NLM:

Further study details as provided by Nektar Therapeutics:

Primary Outcome Measures:
  • Objective Response Rate (ORR) as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 12 Months ]

Enrollment: 70
Study Start Date: October 2008
Study Completion Date: January 2012
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NKTR-102 14 day
Drug: NKTR-102
NKTR-102 given on a q14 day schedule
Experimental: NKTR-102 21 days
Drug: NKTR-102
NKTR-102 given on a q21 day schedule


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Inoperable metastatic or locally advanced breast cancer
  2. No more than 2 prior chemotherapy regimens given in a metastatic or locally advanced setting and prior treatment in the metastatic setting must have included a taxane

Exclusion Criteria:

  1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to Day 1 of Cycle 1
  2. Patients who have had any major surgery within 4 weeks prior to Day 1 of Cycle or minor surgery within 2 weeks prior to Day 1 of Cycle 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00802945

United States, California
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90089-9177
Desert Hematology Oncology Medical Group
Rancho Mirage, California, United States, 92270
Stockton Hematology/Oncology
Stockton, California, United States, 95204
United States, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32224
United States, Kentucky
Louisville Oncology Clinical Research Program
Louisville, Kentucky, United States, 40207
United States, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905
United States, Rhode Island
Pharma Resource
East Providence, Rhode Island, United States, 02915
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22908
Institut Jules Bordet
Bruxelles, Belgium, 2-2-541-72-26
UZ Antwerpen
Edgem, Belgium, 2650
De Pintelaan 1885
Gent, Belgium, 9000
CHU de Liege
Liege, Belgium, 4000
GasthuisZusters Antwerpen
Wilrijk, Belgium, 2610
United Kingdom
Clatterbridge Centre for Oncology
Bebington, United Kingdom, CH63 3J7
Velindre Hospital
Cardiff, United Kingdom, CH14 2TL
Beatson Oncology Center
Glasgow, United Kingdom, G12 ONY
St James University Hospital
Leed, United Kingdom, LS97TF
Nottingham City Hospital
Nottingham, United Kingdom, NG5 1PB
Weston Park Hospital
Sheffield, United Kingdom, S10 2SJ
Sponsors and Collaborators
Nektar Therapeutics
Study Director: Ivan Gergel, MD Nektar Therapeutics
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Nektar Therapeutics Identifier: NCT00802945     History of Changes
Other Study ID Numbers: 08-PIR-05
Study First Received: December 4, 2008
Last Updated: August 12, 2014

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on September 20, 2017